Influence of Albumin Treatment Duration on Outcome of Terlipressin Therapy in Patients With HRS ‐ AKI
Liver International · 2026-11 · 46 (11)
DOI: 10.1111/liv.70888 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Liver International, online erschienen am 30.09.2026. Verfasst von Eva Maria Schleicher und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany. Hauptthemen laut MEDLINE: Acute Kidney Injury, Albumins, Hepatorenal Syndrome, Terlipressin. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Aims Volume expansion with albumin is recommended to establish a diagnosis of hepatorenal syndrome–acute kidney injury (HRS‐AKI). The optimal duration of albumin administration is debated and requires balancing the risk of overtreatment with the need for timely diagnosis and treatment. Therefore, this study aimed to compare the impact of different albumin treatment durations on terlipressin response and the prognosis of patients with HRS‐AKI treated with terlipressin and albumin.
Methods
This multicenter, retrospective secondary analysis included patients with suspected HRS‐AKI who were treated with terlipressin and albumin at 12 German centers. One hundred forty five patients were available for further analysis. The cohort was dichotomized into patients treated with albumin for < 24 h and for 24–60 h before initiation of terlipressin. Patients were followed for treatment response to terlipressin, need for haemodialysis (HD), survival, or liver transplantation (LT).
Results
Median MELD score of the cohort was 25 [IQR 21; 31]. During follow‐up, 59 patients (40.7%) achieved a complete response to treatment with terlipressin, and 96 patients (66.2%) died or received an LT. Response rates to terlipressin therapy did not differ between albumin treatment groups (< 24 h vs. 24–60 h). In multivariable competing risk models, treatment duration of albumin was not associated with any response to terlipressin, considering death and LT as competing events. Of note, albumin treatment duration did not affect HD−/LT‐free survival.
Conclusion
Extending albumin treatment beyond 24 h had no impact on treatment response to terlipressin and albumin or HD‐/LT‐free survival in patients with HRS‐AKI. Clinical Trial Number NCT 06161766
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.
- Department of Internal Medicine B, University Hospital Münster, Münster, Germany.
- Department of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
- Department of Gastroenterology, Hepatology and Transplant Medicine, University of Duisburg-Essen, Essen, Germany.
- Medical Clinic 1, University Hospital, Goethe-University Frankfurt, Frankfurt am Main, Germany.
- Department of Internal Medicine IV, Jena University Hospital, Jena, Germany.
ORCID-Profile: Christian Labenz, Frank Erhard Uschner, Julian Pohl, Moritz Passenberg, Michael Praktiknjo, Marcus Maximilian Mücke, Henrik Karbannek, Marlene Reincke, Paul Jamme, Julian Cardinal von Widdern, Christoph Welsch, Jonel Trebicka, Cornelius Engelmann, Jassin Rashidi-Alavijeh, Cristina Ripoll, Dominik Bettinger
Zitieren
APA
Schleicher, E. M., Labenz, C., Uschner, F. E., Pohl, J., Passenberg, M., Praktiknjo, M., Mücke, M. M., Karbannek, H., Böhling, N., Große, K., Reincke, M., Schütte, S., Jamme, P., von Widdern, J. C., Welsch, C., Trebicka, J., Engelmann, C., Rashidi-Alavijeh, J., Ripoll, C., …, & German cirrhosis study group (2026). Influence of Albumin Treatment Duration on Outcome of Terlipressin Therapy in Patients With HRS ‐ AKI. Liver International, 46(11). https://doi.org/10.1111/liv.70888
Vancouver
Schleicher EM, Labenz C, Uschner FE, Pohl J, Passenberg M, Praktiknjo M, et al. Influence of Albumin Treatment Duration on Outcome of Terlipressin Therapy in Patients With HRS ‐ AKI. Liver International. 2026;46(11). doi:10.1111/liv.70888
BibTeX
@article{Schleicher2026,
author = {Schleicher, Eva Maria and Labenz, Christian and Uschner, Frank Erhard and Pohl, Julian and Passenberg, Moritz and Praktiknjo, Michael and Mücke, Marcus Maximilian and Karbannek, Henrik and Böhling, Nina and Große, Karsten and Reincke, Marlene and Schütte, Sarah and Jamme, Paul and von Widdern, Julian Cardinal and Welsch, Christoph and Trebicka, Jonel and Engelmann, Cornelius and Rashidi-Alavijeh, Jassin and Ripoll, Cristina and Bettinger, Dominik and German cirrhosis study group, German cirrhosis study group},
title = {Influence of Albumin Treatment Duration on Outcome of Terlipressin Therapy in Patients With HRS ‐ AKI},
journal = {Liver International},
year = {2026},
volume = {46},
number = {11},
doi = {10.1111/liv.70888}
}
EUVIMED